Eli Lilly and Company

NYSE:LLY

Drug Manufacturers - General

Healthcare
$1,382.54 -0.95%

-$10.54 today

Market cap
$1.30T
Beta
0.52
P/E (TTM)
39.0
EPS (TTM)
$28.26
Dividend yield
0.59%
52W Low $623.78High $1,182.73

Volume 2.58M

Average 3.19M

LLY Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Eli Lilly and CompanyNYSE: LLY

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation growth accelerates

Q2 FY2026 stock-based compensation of $201M rose 8.6% year over year, ahead of the +5.8% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 24.8% from the prior quarter. Over 3 fiscal years it compounded at +19.0% a year.

Context

  • Stock-based compensation amounted to 1.0% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +8.6% holds above the trailing-twelve-month pace of +5.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$201M+24.8% QoQ
Last fiscal yearDec 2025
$626M-3.0% YoY
LTMJun 2026
$649.2M+5.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.6%——
1 year-3.0%——
3-year CAGR+19.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
626M USD
Year-over-year change
-3.0%
4-year CAGR
+16.2%

Stock-Based Compensation vs competitors

How LLY compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +5.8% is the 5th highest of 8, against a peer median of +7.6%.
  • Stock-based compensation amounts to 0.8% of revenue for LLY, versus a peer median of 1.3%.
LLY Competitors
Stock-Based Compensation for LLY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$1.42B USD+11.0%+6.0%1.4%
ABBVAbbVie Inc.LTM Jun 2026$976M USD+4.5%+12.5%1.5%
PFEPfizer Inc.LTM Jun 2026$947M USD+14.9%-2.9%1.5%
MRKMerck & Co., Inc.LTM Jun 2026$892M USD+12.5%—1.3%
LLYEli Lilly and CompanyLTM Jun 2026$649.2M USD+5.8%+19.0%0.8%
NVSNovartis AGLTM Jun 2026$571M USD-45.9%—1.0%
AMGNAmgen Inc.LTM Jun 2026$492M USD-3.9%+7.2%1.3%
SNYSanofiLTM Jun 2026€184M EUR+7.6%—0.4%
AZNAstraZeneca PLCLTM Sep 2026$0 USD——0.0%
NVONovo Nordisk A/SLTM Jun 2026DKK 0 DKK——0.0%
Peer median (excluding LLY) —+7.6%+6.6%1.3%

Competitors are the stored peer set for LLY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income5.58B6.24B5.24B10.59B20.64B
Depreciation & Amortization1.55B1.52B1.53B1.77B2B
Deferred Income Tax(802.3M)(2.19B)(2.34B)(2.68B)(1.71B)
Stock-Based Compensation342.8M371.1M628.5M645.6M626M
Change in Working Capital(1.01B)(800K)(3.06B)(5.39B)(8.09B)
Accounts Receivables(1.28B)(299.6M)(2.45B)(2.16B)(7B)
Inventory(235.9M)(599.7M)(1.43B)(2.51B)(4.67B)
Accounts Payables(1.01B)1.33B4.27B2.61B10.19B
Other Working Capital1.52B(433.2M)(3.45B)(3.33B)(6.61B)
Other Non-Cash Items1.71B1.63B2.24B3.88B3.35B
Operating Cash Flow7.37B7.59B4.24B8.82B16.81B
Capital Expenditures(1.98B)(2.99B)(7.39B)(5.06B)(7.84B)
Acquisitions (Net)(747.4M)(327.2M)(1.04B)(947.7M)(661M)
Purchases of Investments(1.01B)(707.6M)(829M)(775.8M)(645M)
Sales of Investments847.4M463.6M700.3M522.5M964M
Other Investing Activities(644.3M)(1.34B)(2.53B)303.1M(2.79B)
Investing Cash Flow(2.87B)(3.76B)(7.15B)(9.3B)(10.97B)
Debt Repayment501.4M(62M)8.65B8.9B8.05B
Common Stock Issued00000
Common Stock Repurchased(1.25B)(1.5B)(750M)(2.5B)(4.11B)
Dividends Paid(3.09B)(3.54B)(4.07B)(4.68B)(5.38B)
Other Financing Activities(295.9M)(308.9M)(335M)(490.6M)(772M)
Financing Cash Flow(4.13B)(5.41B)3.5B1.23B(2.21B)
Effect of Forex Changes(205.7M)(167.6M)168.6M(296.7M)372M
Net Change in Cash161.4M(1.75B)751.6M449.8M4B
Free Cash Flow5.39B4.6B(3.15B)3.76B8.97B

Eli Lilly and Company

NYSE:LLY

Intrinsic Alpha fair value

Locked

Current Price

$1,382.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.